Anlotinib, a multi-targeted TKI, is a novel anti-tumor drug developed by China which can effectively inhibit the effects of VEGF/FGFR/PDGF-BB mediated regulatory pathway of tumor angiogenesis. This evidence concerns the gene VEGFA and neoplasm.